CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Doxycycline Monohydrate +1 moredrug
Likely dose
Doxycycline Monohydrate 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00829790
NCT00829790Phase 1Completed

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Study of Doxycycline Monohydrate 25 mg as a 5mL Oral Suspension Under Fed Conditions

Teva Pharmaceuticals USA·interventional·Posted Jan 27, 2009·Updated Aug 19, 2024

In Brief

A Phase 1 clinical trial evaluating Doxycycline Monohydrate for Healthy. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The objective of this study was to compare the rate of absorption and the oral bioavailability of a test formulation of doxycycline monohydrate 1 x 25 mg (5mL) oral suspension manufactured by IVAX Pharmaceuticals, Inc. and distributed by TEVA Pharmaceuticals USA to an equivalent oral dose of the commercially available reference product, Vibramycin Monohydrate® manufactured by Pfizer, Inc. Following an overnight fast of at least 10 hours, subjects consumed a standard high-calorie. high-fat breakfast meal. This standard breakfast meal began 30 minutes prior to each dose.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2009
Enrollment StartOct 1, 2006
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago

Interventions

Doxycycline Monohydratedrug

25 mg 5mL oral dose

Doxycycline Monohydratedrug

25 mg 5 mL dose